Sun Pharma looks to outshine rival bids with $13 billion Organon offer

Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the Indian drug giant into a global leader in branded and innovative medicines. Sun Pharma is competing with other major players for the US company. The deal, if successful, would see Organon merge with Sun Pharma.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oLTDs8N
via IFTTT

Read More

Sun Pharma wins trademark case against Navi Mumbai company

The Bombay High Court has ruled against a Navi Mumbai drugmaker. The court prohibited the use of brand names 'Absun' and 'Absun Pharma'. This decision favors Sun Pharmaceutical Industries in a decade-long trademark dispute. The court found the names deceptively similar to Sun Pharma's established marks. The ruling prevents confusion among consumers in the pharmaceutical market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c7O6z2v
via IFTTT

Read More

Premji Invest takes stake in NewEra Hospitals to expand capacity, strengthen advanced care network

Premji Invest is backing NewEra Hospitals with a new investment. This funding will help NewEra expand its hospital capacity to 800 beds. The platform will also scale advanced specialty care across Maharashtra. NewEra currently operates three hospitals with 350 beds. The company plans to add three more hospitals in Nagpur. This expansion aims to improve access to high-complexity medical care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y2s1A8X
via IFTTT

Read More

Different packaging, typos expose fake Mounjaro racket

Gurugram authorities uncovered a counterfeit Mounjaro operation. Police seized fake diabetes and weight loss injections valued at ₹70 lakh. The alleged mastermind, Avi Sharma, procured raw materials from China. The investigation revealed significant differences in packaging and typographical errors on the fake products. Sharma was arrested for producing these illicit drugs to increase his income.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cHDJheB
via IFTTT

Read More

Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol

Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks a significant milestone for Cipla, reinforcing its leadership in the respiratory segment. The approval enhances Cipla's US portfolio, offering a therapeutic equivalent to a key branded medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2C6WKwh
via IFTTT

Read More

USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facility

Ajanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra from April 13–21, 2026. The company stated it will respond within the stipulated timeframe, while noting that Form-483 is issued when inspectors observe potential regulatory violations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WjGbXS1
via IFTTT

Read More

Lupin launches generic anti-diabetic tablets in US

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydrochloride extended-release tablets. The US Food and Drug Administration approved the drug. Lupin's product is bioequivalent to Xigduo XR. This launch offers a new treatment option for diabetic patients in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzWucXo
via IFTTT

Read More